Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer’s disease with hydromethylthionine mesylate using external control data

Key Points

• Evaluate the efficacy of hydromethylthionine mesylate in treating tau pathology associated with mild cognitive impairment and Alzheimer's disease.
• Compared HMTM treatment with existing control data from CPAD and ADNI.
• Utilized meta-analytic controls for broader analysis of treatment efficacy.
• Evidence suggests HMTM treatment offers significant clinical benefits.
• Treatment was found to be accessible with low burden for both patients and physicians.